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Summary The present study was designed in order to evaluate the response rate and the toxicity of
continuous infusion of Interleukin 2 (IL2) in patients over 65 with metastatic renal cell carcinoma. Twenty-five
patients, median age 69 (range 65-77), without any prior systemic anticancer therapy received a continuous
infusion of IL2 at a dose of 18 x 106 ium2 d' for 2 periods of 5 days separated by a 6 day break. Toxicity
was not different compared with younger patients (e.g. fever, hypotension, rise in creatinine level), except for
cardiac toxicity which was of great concern. Despite normal cardiac tests prior to inclusion into the study,
abnormalities of the cardiac rhythm ranging from tachycardia to ventricular extrasystoles occurred in 44% of
the patients and IL2 cardiac toxicity was responsible for one toxic death. Three objective responses, i.e. one
partial and two complete persistent responses, were seen in 22 evaluable patients. Thus, if age does not seem to
modify the potential for response to IL2 therapy, cardiac toxicity appears as a limiting factor for intravenous
schedules of IL2.
Although renal cell carcinoma is a relatively rare tumour, its
natural history has at least two remarkable points, i.e. the
highest incidence occurs at 65 years of age and 50 to 60% of
the patients develop distant metastases (Holland, 1977; Rit-
chie et al., 1987). Until the eighties, attempts to treat wide-
spread diseases were not successful and renal cancer is
considered as a radio-resistant and chemoresistant tumour
(Finney, 1973; Droz et al., 1988).
Therefore, the 30% response rate, with 10% complete
response in patients treated by intravenous recombinant
Interleukin-2 (IL2) first reported by Rosenberg et al. (1987),
was considered as a possible breakthrough in this disease.
Further studies, though with a generally lower dose of IL2
and lower response rate, unequivocally confirmed the activity
of IL2 in metastatic renal cell carcinoma (West et al., 1987;
Negrier et al., 1990).
Nevertheless, transient toxic effects of IL2 therapy are
unavoidable, and no predictive factor for response to IL2
therapy is known yet. Responding patients remain a
minority. The justification of IL2 therapy in all patients is
still a matter of debate. Using the West schedule (West et al.,
1987), we conducted a phase II trial of intravenous IL2 in
metastatic renal cell carcinoma restricted to patients over 65
years of age. This study reports the characteristics of the
patients, the toxic events and the responses observed with
IL2 in this population.
Patients and methods
Patients
Between October 1987 and January 1991, 33 patients over 65
with metastatic renal cell carcinoma were referred to our
institute. Eligible patients had to meet the following criteria:
histologically documented evidence of metastatic renal cell
carcinoma with measurable progressive disease, no prior
chemotherapy or extensive radiotherapy in the last 4 weeks
prior to registration, an ambulatory performance status
(ECOG 0-1, Karnofsky >80%), blood cell count, serum
bilirubin and creatinine within the normal range, no evidence
of brain metastases at CT scan. Patients were excluded if
they had a significant history or current evidence of serious
organ pathology.
Twenty five patients were eligible and eight were excluded.
The main reasons of exclusion were: Karnofsky's score
<80% (3), brain metastases (2), refusal (2), severe hyper-
calcemia (1). The age of excluded patients ranged from 66 to
75 (median 70). Excluded patients received palliative
treatments and/or chemotherapy as phase II studies.
The characteristics of the 25 eligible patients are detailed in
Table I. There were 16 males and nine females; median age
was 69 (range 65-77). None of them had received prior
treatment except surgery (23 nephrectomy/25).
All patients were required to give informed consent prior
to participation in the study.
Supportive care and monitoring
Before inclusion each patient underwent a cardiac evaluation
which consisted in E.C.G. and ultrasound cardiography with
determination of the left ventricular work index.
All patients were monitored daily during the therapy by
physical examination and measurement of cardiac rhythm,
blood pressure, temperature and weight. Full blood count
and full biochemical analysis were also performed daily. A
chest X-ray was required before treatment and was repeated
twice weekly. All side effects were registered daily and
evaluated according to the WHO criteria (Miller et al., 1981).
Additional treatment included systemic antibiotic (peflacin).
Vascular filling was assumed by 20% albumin infusion in
order to maintain central venous pressure within the normal
range or when hypotension occurred. In case of persistent
hypotension, albumin infusion was prolonged and dopamin
was added in a progressive dosage (0.5 to 1.5 tLg k-' min-')
until blood pressure correction. Fever was routinely treated
by acetaminophen, and indomethacin was added in case of
grade 4 fever.
Treatment
Treatment protocol was reviewed and accepted by the ethical
committee of University C. Bernard in Lyon.
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Table I Principal characteristics of the 25 patients at time of
inclusion
Patient
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Sex
F
M
M
M
F
M
F
M
M
M
M
F
M
F
F
F
M
M
M
M
M
F
M
F
M
Age
70
69
77
72
73
67
66
65
66
73
66
69
69
67
69
67
72
70
68
77
71
69
68
69
72
Prior
nephrectomy
+
+
+
+
+
+
Number of
tumour sites
3
2
2
3
2
2
1
3
1
2
1
2
2
2
3
3
3
3
1
2
1
2
1
1
2
Time between
primary
tumour and
metastases
(months)
6
72
0
0
9
0
0
0
60
18
0
0
0
6
0
0
0
0
3
72
6
0
84
24
0
Patients received rIL2 as a 5-day intravenous (i.v.) con-
tinuous infusion, at a dose of 18 x 106 ium2 d' followed
by a 6-day break. A second 5-day continuous infusion at the
same dose was started at the end of the rest period. After
two identical induction cycles with 3 week rest in between,
patients whose disease was at least stable received four
maintenance cycles of rIL2 at 18 x 106 iu m-2 d-l for 5 days.
These cycles started 3 weeks following completion of the
second induction cycle; each maintenance treatment was
repeated every 4 weeks if progression did not occur.
Recombinant IL-2 was supplied by Eurocetus B.V. Am-
sterdam. The Netherlands. Its specific activity was 18 x 106
International Units per milligram of protein. The dry-frozen
product was reconstituted with 1.2 ml of sterile water; 0.1 ml
of the solution, corresponding to 1,800,000 iu IL-2, was
administered via an electric pump through a standard sub-
clavian catheter as a continuous infusion over 24 h, but the
drug was prepared every 12 h by dilution in 50 ml of 5%
dextrose. A close monitoring was performed during each
cycle of therapy.
Evaulation ofresponse to treatment
Response was considered as complete when all measurable
tumour had disappeared for a period of at least 1 month.
Partial response was a decrease by at least 50% of the sum of
the products of all measurable disease with no evidence of
any new lesion. Progressive disease was defined as an increase
of at least 25% in one of the measurable lesions or by any
additional lesion. The absence of progression was verified
between the first and second induction cycles by physical
examination and chest X-ray. Evaluation was performed 3
weeks after the second induction cycle and 3 weeks after the
last maintenance cycle.
Results
Administration ofIL2
Among the 25 patients treated, 19 received a second
induction course and six were given at least one maintenance
cycle. The mean dose of IL2 administered was of 15 x 106 iu
m-2 d-l (median dose: 18 x 106ium-2d-').
76% ofpatients received at least 70% of the planned dose
during induction course 1 and 61% during course 2.
Toxicity
All patients were evaluable for toxicity, and toxic events are
summarised in Tables II, III and IV. One patient was with-
drawn early from the study (after a 4-day infusion on first
cycle) because of active infection and iatrogenic
pneumothorax. One toxic death occurred in a patient of 65,
at the end of the second period of the first induction course.
This patient had normal cardiac tests prior to joining the
study (E.C.G., ultrasonography). During IL2 therapy,
important asthenia and hypotension (grade 3) were noted.
Hypotension was controlled by dopamine infusion. On the
last day of treatment repeated ventricular extrasystoles
appeared but regressed after intravenous injection of
amiodarone and IL2 interruption. Nevertheless, though
metabolic and biochemical blood controls were normal,
arrhythmia reoccurred, once as a supraventricular tachycar-
dia (pulse 200min-') and then as runs of extrasystoles. Both
episodes were controlled again by amiodarone which was
then administered as a continuous infusion. Three hours
later, extrasystoles associated with hypotension, then a ven-
tricular fibrillation occurred. Specific treatments (electric
shock, epinephrine injection) failed to reduce this ventricular
fibrillation and the patient died 12 h after cessation of IL2;
the family refused the autopsy. Cardiac toxicity was noted in
11/25 (44%) of the patients and appeared mostly as cardiac
rhythm abnormalities ranging from tachycardia (n = 5) to
ventricular extrasystoles (n = 6). Three patients developed a
grade 4 (WHO) hypotension which resolved after colloid and
Table II Hypotention and fever according to the WHO grades
observed during all cycles of therapy
WHO grades
1 2 3 4 Total Percentage
Hypotension 1 6 11 3 23 92%
Fever 1 13 6 - 25 100%
For each patient, the maximum severity through the successive
cycles is considered.
Table III Toxicities registered during all cycles of IL2 therapy other
than fever and hypotension
Adverse event Incidence (%)
Erythema 64
Oliguria 60
Diarrhoea 56
Neurotoxicity 52
Nausea or vomiting 52
Pruritus 48
Cardiac rhythm disturbances 44
Dyspneoa 28
Oedema 20
Urinary retention 8
Cyanosis 8
Toxic death (1 patient) 4
All these toxicities were evaluated as grade 1 to 3 (WHO).
Table IV Biological changes during all cycles of therapy according
to the WHO grades
WHO grades
Parameter tested 1 2 3 4 Total Percentage
Creatinine 5 9 3 1 18 72%
Bilirubin 6 1 1 - 8 32%
SGOT 7 1 - - 8 32%
Hemoglobin 5 6 5 1 16 64%
White blood cells 2 - - - 2 8%
Platelets 1 1 2 8%INTERLEUKIN-2 IN PATIENTS OVER 65 725
dopamine infusions in two cases and requested interruption
of the therapy in one. Fever was present in all patients but
routinely well controlled by acetaminophen; the use of
indomethacin was restricted to a few cases (e.g. two patients).
Gastro-intestinal signs of moderate severity were commonly
observed; in three patients, however, vomiting and diarrhoea
required dose modifications at almost each successive course.
Weight gain below 5% was observed in 15 patients, but only
two patients overloaded 10% of their basal weight.
Renal toxicity was of great concern with a rise of
creatinine levels over 300lAg 1-' in 18/25 patients but dose
modification was required in a few cases only (i.e. 2/25).
Hepatic and haematological disturbances were also frequent
but always transient and moderate. Of note, the number of
transfusional requirements was particualarly low, i.e. four red
blood cell transfusions and no platelet transfusion.
Once treatment was completed all toxicities of rIL2
resolved within 1 to 2 weeks leaving no residual deficit.
Response to therapy
Three patients were not evaluable i.e. one early withdrawal
(after 4 days of treatment for catheter-related complications),
one toxic death and one patient who was considered a
posteriori not to have significant measurable lesions
(<1 cm). Evaluation of the 22 remaining patients showed
one partial and two complete responses, giving an overall
response rate of 3/25 with three responders in 22 evaluable
patients. Details of responding patients are shown in Table
V. In the two patients who are in complete remission a
partial response (i.e. more than 50% tumour regression) was
already achieved after the two induction courses; the dis-
appearance of all lesions was observed respectively after two
and four maintenance cycles. Eight patients were considered
as stable disease respectively for 4 +, 6, 6 +, 7, 7 +, 9, 11 +
and 12 + months and 11 patients were progressive. Two
patients classified as stable had indeed tumour regression. In
one patient five pulmonary metastatic nodules disappeared
whereas one residual lesion slightly increased in size (increase
<25%). This patient, because of the occurrence of severe
hypotension during IL2 therapy, refused to carry on treat-
ment. He then received alpha Interferon (18 x 106 U thrice a
week) and the residual mass was reduced by approximately
75%. The status of this patient has remained stable for 11
months. In another patient two metastatic abdominal lymph
nodes disappeared whereas bone lesions were stable on
radiolabelled bone scan. The status of the patient has been
unchanged for 12 months.
Discussion
This is, to our knowledge, the first report of IL2 therapy in a
group of patients of more than 65 years with renal cell
carcinoma. Since the potential impairments or failure of
different organs are of great concern in this particular
population, the schedule described by West et al., 1987, was
used in a view to reduce toxicity. The amount of drug
administered was over 70% of the planned dose in almost all
the patients during the first course. Types of toxicities
observed were comparable to what had been observed in
younger patients and mostly manageable using symptomatic
treatments and transient interruptions ofrIL2 infusion. How-
ever, cardiac toxicity was of great concern; cardiac rhythm
disturbances occurred in 44% of the patients and cardiac
toxicity was clearly involved in the toxic death. Although
cardiac toxicity of IL2 was already known and anlaysed,
such a severity and incidence were not commonly reported in
previous studies, specially when continuous infusion was used
(Rosenberg et al., 1987; West et al., 1987; Fischer et al.,
Table V Characteristics of the responding patients
Response
duration
Patients Sex Age Nephrectomy Tumour sites (months)
1 M 69 + Lung/Kidney PR (4)
2 M 75 + Adrenal gland/ CR (18 +)
Abdominal mass
3 M 65 + Lung CR (15+)
PR: Partial response, CR: Complete response.
1988; Nora et al., 1989; Negrier et al., 1990; Siegel et al.,
1991). Obviously, despite normal cardiologic tests prior to
treatment, the heart of patients over 65 is particularly sensi-
tive to IL2 toxicity. As in previous reports (Rosenberg et al.,
1987; West et al., 1987; Fischer et al., 1988; Nora et al., 1989;
Negrier et al., 1990) fever, hypotension and renal failure were
the most common other side effects encountered. They also
appeared transient and limited to the treatment period.
Three responses were seen and two complete remissions
were achieved i.e. two durable persistent complete responses
and one partial response. In addition, among the eight
patients categorised as stable, two patients also had
significant persistent tumour regressions.
These results are not different from those reported in
cohorts of younger patients (Rosenberg et al., 1987; Fischer
et al., 1988; Nora et al., 1989; Negrier et al., 1990).
IL2 therapy which induces, according to different authors,
a response rate of 20 to 30% is, in this respect, beneficial
only to a minority of patients (Rosenberg et al., 1987; Fis-
cher et al., 1988; Nora et al., 1989; Negrier et al., 1990).
Nevertheless, the 5 to 10% complete response rate should not
be disregarded in a disease in which nothing but rIL2 and
Interferon alpha has really proved efficient (Quesada et al.,
1985; Bergerat et al., 1988). To an individual and ethical
point of view, we think we have to give a maximum of
patients the chance to reach complete remission through
immunotherapy. Except for some preliminary data, no
predictive factor of response is known yet; and our study
indicates that age does not influence the potential of tumour
regression induced by in vivo IL2 stimulation (Blay et al.,
1990).
However, the schedule of treatment and the drugs to use,
i.e. rIL2 vs IFN vs both of them, are still debatable. Prior
studies reported interesting results with ambulatory therapy
with Interferon, but the duration of these treatment
schedules, i.e. 6 to 12 months, is not adapted to a disease
with a crude median survival of 8 to 12 months (Ritchie et
al., 1987; Deforges et al., 1988; Elson et al., 1988; Philip et
al., 1989). More recently, a 'home therapy regimen' was
proposed using a subcutaneous combination of rIL2 and
Interferon alpha (Atzpodien et al., 1990). This regimen did
not raise any life threatening toxicity and the response rate
obtained does not signficantly differ from those obtained
with continuous infusion of IL2. To our point ofview, a first
line immunotherapy should be proposed to a maximum of
patients in order to select those who are sensitive to this kind
of therapy, and long lasting schedules should be restricted to
responding patients. As such, the combined subcutaneous
schedules of IL2 and IFN could represent an adapted deal to
this situation. Prolonged therapy in responding patients must
be evaluated in randomised trials.
In conclusion, the present study demonstrates that rIL2
continuous infusion is feasible, but has a particular cardiac
toxicity in patients over 65 years old. The efficacy of rIL2 in
this group is not different from what it is in the general
population of patients with metastatic renal cell cancer.726 S. NEGRIER et al.
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